1. Home
  2. APRE

as of 12-12-2025 4:00pm EST

$0.93
$0.01
-1.07%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Chart Type:
Time Range:
Founded: 2006 Country:
United States
United States
Employees: N/A City: DOYLESTOWN
Market Cap: 6.9M IPO Year: 2019
Target Price: $20.00 AVG Volume (30 days): 71.8K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.14 EPS Growth: N/A
52 Week Low/High: $0.90 - $5.00 Next Earning Date: 11-12-2025
Revenue: $488,239 Revenue Growth: -62.75%
Revenue Growth (this year): -80.92% Revenue Growth (next year): N/A

AI-Powered APRE Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 74.31%
74.31%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Aprea Therapeutics Inc. (APRE)

Hamill John P.

SrVP/CFO/Prin Fin & Acct Ofcr

Buy
APRE Dec 10, 2025

Avg Cost/Share

$1.17

Shares

5,000

Total Value

$5,825.00

Owned After

27,733

SEC Form 4

Duey Marc

Director

Buy
APRE Dec 10, 2025

Avg Cost/Share

$1.17

Shares

21,459

Total Value

$24,999.74

Owned After

256,155

SEC Form 4

Latest Aprea Therapeutics Inc. News

APRE Breaking Stock News: Dive into APRE Ticker-Specific Updates for Smart Investing

All APRE News

Share on Social Networks: